Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ESB Thoracic

Phase 3Small molecule

GGeorge Washington University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erector Spinae BlockRecruiting

Erector Spinae BlockPhase 3

Recruiting

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Erector Spinae Block

NCT05521789

Clinical

Trials by Indication[1]

Erector Spinae Block1 trial

Erector Spinae Block for Thoracic Surgery

Recruiting·GGeorge Washington University·Phase 4·NCT05521789·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ESB Thoracic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ESB Thoracic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ESB Thoracic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — George Washington University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGeorge Washington University

Related News